Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Na.O3Se.5H2O |
Molecular Weight | 263.01 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Na+].[Na+].[O-][Se]([O-])=O
InChI
InChIKey=TUANAMBRHOLYTH-UHFFFAOYSA-L
InChI=1S/2Na.H2O3Se.5H2O/c;;1-4(2)3;;;;;/h;;(H2,1,2,3);5*1H2/q2*+1;;;;;;/p-2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O3Se |
Molecular Weight | 128.97 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
The selenite anion is a selenium oxoanion with the chemical formula SeO2−3. A selenite (Se) is a compound that contains this ion. Sodium selenite is an inorganic form of the trace element selenium with potential antineoplastic activity. It was documented that Se deficiency observed in some countries and/or geographic regions (e.g. Keshan region in China), is associated with an increased morbidity and mortality of neoplastic diseases. To correct this problem a number of organic and inorganic selenium compounds were developed and tested. However, it is now firmly established that only an inorganic sodium selenite with four-valent Se, and not that with six-valent (selenate) cation shows anticancer activity. Selenite can undergo redox reaction, for example with protein's sulfhydryl groups expressed on the surface of tumor cells. In this way selenite prevents non-enzymatic formation of parafibrin that coats tumors cells and hence presents them as 'self' to the innate cellular immune system. Consequently, macrophages of the lymphatic system do not recognize neoplastic cells as 'foreign' bodies and spare them from the immune destruction. Sodium selenite also showed promise as a cost-effective, nontoxic anti-inflammatory agent. Treatment with sodium selenite lowers reactive oxygen species (ROS) production, causes a spontaneous reduction in lymphedema volume, increases the efficacy of physical therapy for lymphedema, and reduces the incidence of erysipelas infections in patients with chronic lymphedema. Limited evidence has been presented though that intakes of selenium greater than the amount needed to allow full expression of selenoproteins may have chemopreventive effects against cancer. Controlled intervention studies are needed to fully evaluate selenium as a cancer chemopreventive agent. The US Food and Drug Administration approved a selenium supplement to animal diets; the most common form is sodium selenite for pet foods.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.5 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
200 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26102212/ |
4.5 mg/m² single, intravenous dose: 4.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
SELENITE ION plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 mg 1 times / day multiple, intravenous Highest studied dose Dose: 1 mg, 1 times / day Route: intravenous Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, adult n = 296 Health Status: unhealthy Condition: severe sepsis Age Group: adult Sex: M+F Population Size: 296 Sources: |
Other AEs: Respiratory failure... Other AEs: Respiratory failure (grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Respiratory failure | grade 5 | 1 mg 1 times / day multiple, intravenous Highest studied dose Dose: 1 mg, 1 times / day Route: intravenous Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, adult n = 296 Health Status: unhealthy Condition: severe sepsis Age Group: adult Sex: M+F Population Size: 296 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11293463
Extradietary supplementation of selenium at the dosage of 200 micrograms per day is generally considered safe and adequate for an adult of average weight subsisting on the typical American diet.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:22:10 GMT 2023
by
admin
on
Fri Dec 15 17:22:10 GMT 2023
|
Record UNII |
0WV4L961ZV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90181473
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
134930
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
0WV4L961ZV
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
26970-82-1
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
100000091726
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
C87347
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY | |||
|
SUB22203
Created by
admin on Fri Dec 15 17:22:11 GMT 2023 , Edited by admin on Fri Dec 15 17:22:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |